Seattle Genetics (Nasdaq:SGEN) announced dosing of the first patient in the phase 2 innovaTV 204 clinical trial evaluating the efficacy, safety and tolerability of tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment. As quoted in the press release: Tisotumab vedotin is being … Continued
The post Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin appeared first on Investing News Network.